Dietary fat supplement trial for A-T

Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts movement, vision and speech. The condition can also result in a weakened immune system with frequent infections and an increased risk of cancers such as leukemia and lymphoma. A dietary fat supplement could improve the prognosis and quality of life for Australian children living A-T.

This innovative trial aims to treat mitochondrial dysfunction in A-T using a novel form of anaplerosis.

Children and adults with A-T across Australia are participating in the trial launched by the Federal Health Minister, The Hon. Greg Hunt MP, in 2022.

Redenlab are providing speech, language and mealtime assessments for the children, adolescents and adults in the trial.

For more information, click here.

Related Post

  • Posted on 25 January, 2024
    MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...
    • Posted on 25 January, 2024
      Exposing healthy adults to extended periods of wakefulness is known to induce changes in psychomotor functioning. The effect of fatigue...
      • Posted on 17 January, 2024
        While speech biomarkers of disease have attracted increased interest in recent years, a challenge is that features derived from signal...